C-TRACT Trial: Stenting Gains, Bleeding Costs
This episode breaks down the C-TRACT trial, comparing iliac vein stenting with standard care for post-thrombotic syndrome and highlighting the trial’s strong improvements in symptoms and quality of life.
It also weighs the trade-offs: higher bleeding risk, heavier antithrombotic therapy, and the unresolved questions around long-term stent durability.
Chapter 1
Unblocking the Vein: The C TRACT Trial Breakdown
Dr. James Whitfield
Up to, um, up to fifty percent of our patients who suffer a severe proximal deep vein thrombosis go on to develop post thrombotic syndrome. And, er, for years in the clinic, when that scarred iliac vein causes severe chronic venous hypertension, swelling, skin breakdown, we, we really had to tell them there was very little else we could do beyond compression garments.
Dr. Elena Rodriguez
Right, because interventionalists were placing metallic stents into those clogged iliac veins anyway, but without, uh, without any real randomized evidence to back it up.
Dr. James Whitfield
Exactly. Which is why the C TRACT trial was so necessary. They took two hundred and twenty five patients with moderate to severe post thrombotic syndrome across twenty nine centers in the United States. All of them had imaging confirmed iliac vein obstruction, and they randomized them one to one.
Dr. Elena Rodriguez
One to one comparing endovascular stenting against standard medical care?
Dr. James Whitfield
Yes. Standard care meant twenty to thirty millimeters of mercury compression stockings, therapeutic anticoagulation, and, uh, and wound care. The interventional arm got stenting with non covered nitinol or elgiloy stents twelve millimeters or larger, plus an intensified antithrombotic regimen.
Dr. Elena Rodriguez
And at six months, what did the blinded assessors actually see on the severity scales?
Dr. James Whitfield
On the Venous Clinical Severity Score, or V C S S, the stented group dropped to a mean of eight point one, compared to ten point zero in standard care. That is an adjusted difference of minus two point zero points, with a p value of zero point zero zero one.
Dr. Elena Rodriguez
Wow, minus two points on V C S S is clinically substantial. But what about quality of life?
Dr. James Whitfield
That was even more pronounced. On the VEINES Q O L quality of life scale, the endovascular group scored sixty two point eight, compared to forty eight point six in the control group. That is a fourteen point five point leap, well above the four to six point threshold we consider meaningful clinical change.
Dr. Elena Rodriguez
Fourteen point five points. If you think about the underlying physics, it makes complete sense. An obstructed iliac vein is essentially a clogged main outflow trunk. You open that central pipe with a rigid nitinol scaffold, restore the caliber, and downstream venous pressure drops immediately. The leg stops pooling fluid.
Dr. James Whitfield
Exactly. It is mechanical restoration of flow. But, uh, as you know, putting permanent metal hardware into a low pressure venous system comes with a cost.
Chapter 2
The Antithrombotic Price and Durability
Dr. Elena Rodriguez
And that cost was bleeding, right? Because to keep those large twelve millimeter stents open, you have to run aggressive blood thinners.
Dr. James Whitfield
Precisely. Overall bleeding occurred in eleven point six percent of stented patients versus just three point six percent in the standard care group. That was statistically significant at p equals zero point zero three.
Dr. Elena Rodriguez
Was that driven by major hemorrhages or non major bleeding?
Dr. James Whitfield
It was mostly non major bleeding, nine point eight percent in the stented arm versus two point seven percent in control. And the reason is clear when you look at the medication lists. Seventy one point three percent of stented patients were put on dual antiplatelet therapy or antiplatelets added to anticoagulation, compared to only twenty one percent of control patients.
Dr. Elena Rodriguez
So you buy immediate hemodynamic relief, but you pay for it with an eleven point six percent bleeding risk and a heavy regimen of dual therapy. And, uh, James, what about the durability? C TRACT evaluated primary outcomes at six months, right?
Dr. James Whitfield
Six months, yes. That is the critical caveat. A nitinol stent is a permanent vascular implant. Six months tells us the intervention works acute term, but it does not tell us what happens at twelve, eighteen, or twenty four months.
Dr. Elena Rodriguez
Right, because in young or middle aged patients, long term stent patency, late restenosis, re intervention rates, or even stent fracture are the real questions we need answered before declaring victory.
Dr. James Whitfield
Exactly. It leaves clinicians with a very real trade off in practice. C TRACT gives us rigorous proof that stenting significantly improves symptoms and quality of life at six months for patients who previously had no options. But we are asking them to accept elevated bleeding risks and the lifelong commitment of managing permanent venous hardware.
Dr. Elena Rodriguez
A classic medical dilemma, immediate functional gain versus long term risk management. Alright, good review James, let us keep an eye out for the two year C TRACT follow up data.